Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Fiche publication

Date publication

mars 2019

Journal

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe

Tous les auteurs :
Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30911859

Résumé

The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in advanced gastric/gastroesophageal junction cancer. Results from cohorts 2 and 3, evaluating first-line therapy, are presented.